Improvement of cholestatic episodes in patients with benign recurrent intrahepatic cholestasis (BRIC) treated with rifampicin. A long-term follow-up

References

• Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin Liver Dis. 2004;8(1):133–149, vii.
   PubMedGoogle Scholar
• Karlsen TH, Hov JR. Genetics of cholestatic liver disease in 2010. Curr Opin Gastroenterol. 2010;26(3):251–258.
   PubMed Web of Science ®Google Scholar
• Tygstrup N, Jensen B. Intermittent intrahepatic cholestasis of unknown etiology in five young males from the Faroe Islands. Acta Med Scand. 1969;185(6):523–530.
   PubMedGoogle Scholar
• Folvik G, Hilde O, Helge GO. Benign recurrent intrahepatic cholestasis: review and long-term follow-up of five cases. Scand J Gastroenterol. 2012;47(4):482–488.
   PubMed Web of Science ®Google Scholar
• Strubbe B, Geerts A, Van Vlierberghe H, et al. Progressive familial intrahepatic cholestasis and benign recurrent intrahepatic cholestasis: a review. Acta Gastroenterol Belg. 2012;75(4):405–410.
   PubMed Web of Science ®Google Scholar
• Halawi A, Ibrahim N, Bitar R. Triggers of benign recurrent intrahepatic cholestasis and its pathophysiology: a review of literature. Acta Gastroenterol Belg. 2021;84(3):477–486.
   PubMed Web of Science ®Google Scholar
• Saich R, Collins P, Ala A, et al. Benign recurrent intrahepatic cholestasis with secondary renal impairment treated with extracorporeal albumin dialysis. Eur J Gastroenterol Hepatol. 2005;17(5):585–588.
   PubMed Web of Science ®Google Scholar
• van Ooteghem NA, Klomp LW, van Berge-Henegouwen GP, et al. Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low GGT cholestasis is a clinical continuum. J Hepatol. 2002;36(3):439–443.
   PubMed Web of Science ®Google Scholar
• van der Woerd WL, Houwen RH, van de Graaf SF. Current and future therapies for inherited cholestatic liver diseases. World J Gastroenterol. 2017;23(5):763–775.
   PubMed Web of Science ®Google Scholar
• Salyani A, Barasa L, Rajula A, et al. Benign recurrent intrahepatic cholestasis (BRIC): an African case report. Case Rep Gastrointest Med. 2020;2020:2894293.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Kulkarni AV, Sahoo B, et al. Endoscopic nasobiliary drainage: an effective treatment option for benign recurrent intrahepatic cholestasis (BRIC). BMJ Case Rep. 2017. DOI: 10.1136/bcr-2016-218874
   Google Scholar
• Yakar T, Demir M, Gokturk HS, et al. Nasobiliary drainage for benign recurrent intrahepatic cholestasis in patients refractory to standard therapy. Clin Invest Med. 2016;39(6):27522.
   PubMed Web of Science ®Google Scholar
• Cancado EL, Leitao RM, Carrilho FJ, et al. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am J Gastroenterol. 1998;93(9):1510–1517.
   PubMed Web of Science ®Google Scholar
• Mizuochi T, Kimura A, Tanaka A, et al. Characterization of urinary bile acids in a pediatric BRIC-1 patient: effect of rifampicin treatment. Clin Chim Acta. 2012;413(15–16):1301–1304.
   PubMed Web of Science ®Google Scholar
• Kumagi T, Heathcote EJ. Successfully treated intractable pruritus with rifampin in a case of benign recurrent intrahepatic cholestasis. Clin J Gastroenterol. 2008;1(4):160–163.
   PubMedGoogle Scholar
• Ermis F, Oncu K, Ozel M, et al. Benign recurrent intrahepatic cholestasis: late initial diagnosis in adulthood. Ann Hepatol. 2010;9(2):207–210.
   PubMed Web of Science ®Google Scholar
• Alhebbi H, Peer-Zada AA, Hussaini AA, et al. New paradigms of USP53 disease: normal GGT cholestasis, BRIC, cholangiopathy, and responsiveness to rifampicin. J Hum Genet. 2021;66(2):151–159.
   PubMed Web of Science ®Google Scholar
• Chen H, Wu D, Jiang W, et al. Case report: a novel homozygous variant identified in a Chinese patient with benign recurrent intrahepatic cholestasis-type 1. Front Med. 2021;8:705489.
   Web of Science ®Google Scholar
• Piazzolla M, Castellaneta N, Novelli A, et al. Nonsense variant of ATP8B1 gene in heterozygosis and benign recurrent intrahepatic cholestasis: a case report and review of literature. World J Hepatol. 2020;12(2):64–71.
   PubMed Web of Science ®Google Scholar
• Koukoulioti E, Ziagaki A, Weber SN, et al. Long-Term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease. Hepatology. 2021;74(1):522–524.
   PubMed Web of Science ®Google Scholar
• de Pagter AG, van Berge Henegouwen GP, ten Bokkel Huinink JA, et al. Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives? Gastroenterology. 1976;71(2):202–207.
   PubMed Web of Science ®Google Scholar
• Beuers U, Trauner M, Jansen P, et al. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015;62(1 Suppl):S25–S37.
   PubMed Web of Science ®Google Scholar
• Jonker JW, Liddle C, Downes M. FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol. 2012;130(3–5):147–158.
   PubMed Web of Science ®Google Scholar
• Gerard P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens. 2013;3(1):14–24.
   PubMedGoogle Scholar
• Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 2006;26(8):943–948.
   PubMed Web of Science ®Google Scholar
• Sticova E, Jirsa M, Pawłowska J. New insights in genetic cholestasis: from molecular mechanisms to clinical implications. Can J Gastroenterol Hepatol. 2018;2018:2313675.
   PubMed Web of Science ®Google Scholar
• Stapelbroek JM, van Erpecum KJ, Klomp LWJ, et al. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol. 2010;52(2):258–271.
   PubMed Web of Science ®Google Scholar
• Boyer TD, Lindor KD. Zakim and Boyer’s hepatology: a textbook of liver disease e-book. Amsterdam (Netherlands): Elsevier Health Sciences; 2016.
   Google Scholar
• Mullenbach R, Bennett A, Tetlow N, et al. ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. Gut. 2005;54(6):829–834.
   PubMed Web of Science ®Google Scholar
• Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics. 2007;17(1):47–60.
   PubMed Web of Science ®Google Scholar